Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
VIKING THERAPEUTICS INC (VKTX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$25.79-7.79%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for VKTX yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
sufficient cash to fund operations and pipeline development | A supporting condition in VIKING THERAPEUTICS INC's published investment case. The stated target is cash runway extends beyond 12 months without dilutive financing. | Intact | cash runway falls below 12 months without clear financing plan | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
VKTX is a speculative growth company whose prospects depend on developing obesity medicines, rather than on current earnings. The long-term thesis is in a watch state: clinical work is advancing, but the latest earnings miss and weaker company signals have raised near-term concerns.
The evidence snapshot does not provide a valuation multiple or a clear account of market expectations, so whether VKTX is cheap or expensive versus peers cannot be assessed. It reports low fragility in the pricing signals, but that does not resolve the gap between expectations and the company’s clinical and financial execution.
Near term, losses and research spending are likely to remain central: third-quarter research and development expense rose from the prior-year quarter, and no revenue was reported in the supplied financials. Trial progress includes advancement of VANQUISH, the start of the oral Phase 3 program, and encouraging maintenance-dosing results, but the latest earnings miss and elevated risk of another miss temper that progress.
Over the next year, the thesis hinges on continued progress in VK2735’s Phase 3 obesity trials and evidence that maintenance dosing works as reported. A guidance cut or continued weak jobs data could add pressure, while strong results and guidance from healthcare peers could support sector momentum.
For the next 1 to 3 years, VKTX remains a clinical-development story with meaningful trial progress, no reported revenue, and elevated execution risk. The thesis depends on converting study progress into stronger evidence while managing losses and near-term uncertainty. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A primary condition in VIKING THERAPEUTICS INC's published investment case. The stated target is EPS loss improves from -$1.37 next quarter to less negative by end 2026. |
| Improving |
| EPS loss worsens beyond -$1.5 next quarter or fails to improve by end 2026 |
Diluted EPS: $-1.55 per share FY2026-Q3; GAAP. Published target: EPS loss improves from -$1.37 next quarter to less negative by end 2026. Annual target cannot be compared with a quarterly or TTM observation. Oct 29, 2026-1.55 USD/share · source valueLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
advancement of VK2735 obesity program and other pipeline assets | Despite losses, recent progress in obesity drug VK2735 could lead to future value. | Improving | failure to meet key clinical or regulatory milestones for VK2735 by end 2026 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-4.57 → $-5.03 · observed estimates
$0.00B → $0.01B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-4.57 | $0 | 17 / 17 |
| 2026-07-25 | $-4.57 | $0 | 17 / 17 |
| 2026-07-26 | $-4.57 | $0 | 17 / 17 |
| 2026-07-27 | $-4.57 | $0 | 17 / 17 |
| 2026-07-28 | $-4.57 | $0 | 17 / 17 |
| 2026-07-29 | $-4.77 | $7,349,020 | 15 / 10 |
| 2026-07-30 | $-4.54 | $0 | 17 / 16 |
| 2026-07-31 | $-4.39 | $0 | 17 / 18 |
| 2026-08-01 | $-4.42 | $7,349,020 | 15 / 11 |
| 2026-08-02 | $-4.42 | $7,349,020 | 15 / 11 |
| 2026-08-03 | $-4.42 | $7,349,020 | 15 / 11 |
| 2026-08-04 | $-4.39 | $0 | 17 / 18 |
| 2026-08-05 | $-4.42 | $7,349,020 | 15 / 11 |
| 2026-08-06 | $-4.33 | $0 | 17 / 18 |
| 2026-08-08 | $-4.42 | $7,349,020 | 15 / 11 |
| 2026-08-09 | $-4.33 | $0 | 17 / 18 |
| 2026-08-10 | $-4.33 | $0 | 17 / 18 |
| 2026-08-12 | $-4.42 | $7,349,020 | 15 / 11 |
| 2026-08-13 | $-4.42 | $7,349,020 | 15 / 11 |
| 2026-08-14 | $-4.42 | $7,349,020 | 15 / 11 |
| 2026-08-15 | $-4.42 | $7,349,020 | 15 / 11 |
| 2026-08-16 | $-4.42 | $7,349,020 | 15 / 11 |
| 2026-08-17 | $-4.42 | $7,349,020 | 15 / 11 |
| 2026-08-18 | $-4.42 | $7,349,020 | 15 / 11 |
| 2026-08-19 | $-4.42 | $7,349,020 | 15 / 11 |
| 2026-08-20 | $-4.39 | $7,349,020 | 15 / 11 |
| 2026-08-21 | $-4.39 | $7,349,020 | 15 / 11 |
| 2026-08-22 | $-4.39 | $7,349,020 | 15 / 11 |
| 2026-08-23 | $-4.39 | $7,349,020 | 15 / 11 |
| 2026-08-24 | $-4.39 | $7,349,020 | 15 / 11 |
| 2026-08-25 | $-4.39 | $7,349,020 | 15 / 11 |
| 2026-08-26 | $-4.39 | $7,349,020 | 15 / 11 |
| 2026-08-27 | $-4.39 | $7,349,020 | 15 / 11 |
| 2026-08-28 | $-4.39 | $7,349,020 | 15 / 11 |
| 2026-08-29 | $-4.39 | $7,349,020 | 15 / 11 |
| 2026-08-30 | $-4.39 | $7,349,020 | 15 / 11 |
| 2026-08-31 | $-4.39 | $7,349,020 | 15 / 11 |
| 2026-09-01 | $-4.39 | $7,349,020 | 15 / 11 |
| 2026-09-02 | $-4.39 | $7,349,020 | 15 / 11 |
| 2026-09-03 | $-4.39 | $7,349,020 | 15 / 11 |
| 2026-09-04 | $-4.39 | $7,349,020 | 15 / 11 |
| 2026-09-05 | $-4.39 | $7,349,020 | 15 / 11 |
| 2026-09-06 | $-4.39 | $7,349,020 | 15 / 11 |
| 2026-09-07 | $-4.39 | $7,349,020 | 15 / 11 |
| 2026-09-08 | $-4.39 | $7,349,020 | 15 / 11 |
| 2026-09-09 | $-4.39 | $7,349,020 | 15 / 11 |
| 2026-09-10 | $-4.39 | $7,349,020 | 15 / 11 |
| 2026-09-11 | $-4.39 | $7,349,020 | 15 / 11 |
| 2026-09-12 | $-4.39 | $7,349,020 | 15 / 11 |
| 2026-09-13 | $-4.39 | $7,349,020 | 15 / 11 |
| 2026-09-14 | $-4.39 | $7,349,020 | 15 / 11 |
| 2026-09-15 | $-4.39 | $7,349,020 | 15 / 11 |
| 2026-09-16 | $-4.39 | $7,349,020 | 15 / 11 |
| 2026-09-17 | $-4.39 | $7,349,020 | 15 / 11 |
| 2026-09-18 | $-4.39 | $7,349,020 | 15 / 11 |
| 2026-09-19 | $-4.39 | $7,349,020 | 15 / 11 |
| 2026-09-20 | $-4.39 | $7,349,020 | 15 / 11 |
| 2026-09-21 | $-4.39 | $7,349,020 | 15 / 11 |
| 2026-09-22 | $-4.39 | $7,349,020 | 15 / 11 |
| 2026-09-23 | $-4.39 | $7,349,020 | 15 / 11 |
| 2026-09-24 | $-4.39 | $7,349,020 | 15 / 11 |
| 2026-09-25 | $-4.39 | $7,349,020 | 14 / 10 |
| 2026-09-26 | $-4.39 | $7,349,020 | 14 / 10 |
| 2026-09-27 | $-4.39 | $7,349,020 | 14 / 10 |
| 2026-09-28 | $-4.39 | $7,349,020 | 14 / 10 |
| 2026-09-29 | $-4.39 | $7,349,020 | 14 / 10 |
| 2026-09-30 | $-4.39 | $7,349,020 | 14 / 10 |
| 2026-10-01 | $-4.39 | $7,349,020 | 14 / 10 |
| 2026-10-02 | $-4.39 | $7,349,020 | 14 / 10 |
| 2026-10-03 | $-4.39 | $7,349,020 | 14 / 10 |
| 2026-10-04 | $-4.39 | $7,349,020 | 14 / 10 |
| 2026-10-05 | $-4.39 | $7,349,020 | 14 / 10 |
| 2026-10-06 | $-4.39 | $7,349,020 | 14 / 10 |
| 2026-10-07 | $-4.39 | $7,349,020 | 14 / 10 |
| 2026-10-08 | $-4.39 | $7,349,020 | 14 / 10 |
| 2026-10-09 | $-4.39 | $7,349,020 | 14 / 10 |
| 2026-10-10 | $-4.39 | $7,349,020 | 14 / 10 |
| 2026-10-11 | $-4.39 | $7,349,020 | 14 / 10 |
| 2026-10-12 | $-4.39 | $7,349,020 | 14 / 10 |
| 2026-10-13 | $-4.39 | $7,349,020 | 14 / 10 |
| 2026-10-14 | $-4.39 | $7,349,020 | 14 / 10 |
| 2026-10-15 | $-4.36 | $7,349,020 | 14 / 10 |
| 2026-10-16 | $-4.36 | $7,349,020 | 15 / 10 |
| 2026-10-17 | $-4.36 | $7,349,020 | 15 / 10 |
| 2026-10-18 | $-4.36 | $7,349,020 | 15 / 10 |
| 2026-10-19 | $-4.36 | $7,349,020 | 15 / 10 |
| 2026-10-20 | $-4.36 | $7,349,020 | 15 / 10 |
| 2026-10-21 | $-4.35 | $7,349,020 | 15 / 10 |
| 2026-10-22 | $-4.35 | $7,349,020 | 15 / 10 |
| 2026-10-23 | $-4.35 | $7,349,020 | 15 / 10 |
| 2026-10-24 | $-4.35 | $7,349,020 | 15 / 10 |
| 2026-10-25 | $-4.35 | $7,349,020 | 15 / 10 |
| 2026-10-26 | $-4.35 | $7,349,020 | 15 / 10 |
| 2026-10-27 | $-4.35 | $7,349,020 | 15 / 10 |
| 2026-10-28 | $-4.35 | $7,349,020 | 15 / 10 |
| 2026-10-29 | $-5.11 | $7,349,020 | 15 / 10 |
| 2026-10-30 | $-5.13 | $7,349,020 | 15 / 10 |
| 2026-10-31 | $-5.15 | $7,349,020 | 15 / 10 |
| 2026-11-01 | $-5.15 | $7,349,020 | 15 / 10 |
| 2026-11-02 | $-5.15 | $7,349,020 | 15 / 10 |
| 2026-11-03 | $-5.15 | $7,349,020 | 15 / 10 |
| 2026-11-04 | $-5.03 | $7,349,020 | 15 / 10 |
| 2026-11-05 | $-5.03 | $7,349,020 | 15 / 10 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 19 Buy / Strong Buy · 2 Hold · 0 Sell / Strong Sell
Recent actions · Oct 7–Nov 5 · 3 recorded
0 raises · 1 cuts · 0 unchanged · 1 without a comparable prior
Oct 7, 2026–Nov 5, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.